AMS — Advanced Medical Solutions Group plc

Executive summary

AMS is a UK-headquartered specialist in tissue-healing medical devices (surgical adhesives, sutures, biosurgical collagens, internal fixation, woundcare) selling globally through partners and a growing direct sales force, materially enlarged by the July 2024 Peters Surgical acquisition. Across the period covered, revenue rose from £86.8m (2020) to ~£228.5m (FY25 trading update) with adjusted EBITDA scaling from ~£21m to ~£50m, though group EBITDA margin temporarily compressed (H1 2025: 22.0% vs H1 2024 25.3%) as Peters dilutes mix and US tariffs/integration costs bite. The single most important valuation point today: the bull case rests on the next wave of US FDA approvals (Biosurgical collagens, FDBS, Peters sutures from 2026-27) plus £10m of Peters operational synergies into 2027, against a £50m net-debt balance sheet that the Board guides to ~1x EBITDA by year-end 2025.

Fair value estimate

Range: 270p – 340p per share (£590m – £743m market cap); midpoint ~305p (£667m).

Methodology: EV/EBITDA cross-checked with forward P/E.

• 2026E adj EBITDA: £55–60m (assumes 10–15% growth from FY25 £49.75m, modest margin recovery as Woundcare runs at double-digit margin and Peters synergies build).
• Specialty European med-tech multiples 11–15x EV/EBITDA. Applying 12–14x to £57m midpoint = £684m–£798m EV, less ~£50m net debt → £634m–£748m equity.
• Cross-check on forward P/E: FY25 adj diluted EPS likely ~11.5–12.0p (H1 5.67p + tax/interest headwinds in H2); FY26 ~13–14p. At 20–24x = 260p–336p.

Versus current £534.5m market cap (~245p): absolute upside ~25% to midpoint (range +10% to +40%).

Sector context

ICB Health Care — Medical Equipment. Quality (gross margin ~53–54%, recurring demand) is in line with European specialty med-tech peers; growth (organic mid-teens) is ahead of typical large-cap med-tech but in line with focused specialists; leverage (~1x EBITDA) is below sector average. Listed peers: Smith+Nephew (SN.) — much larger orthopaedic/woundcare; ConvaTec (CTEC) — woundcare/continence overlap; Medartis (MED.SW) and US-listed Integra LifeSciences (IART) for biosurgical/closure comparison.

Investment thesis

• US FDA pipeline is the underappreciated catalyst. A clearly identified sequence of regulatory milestones (US topical adhesives, collagen dental cone 2026, FDBS 2026-27, Peters cardio-vascular sutures 2026-27, drug-eluting collagens 2030) opens addressable markets where AMS is currently absent or sub-scale 2025-09 interim results.
• Peters integration is delivering with quantified £10m operational synergy target by 2027 plus £5–10m commercial synergies within five years, on track per H1 2025 commentary; already visible in 13% H1 organic growth and 86% constant-currency surgical growth 2025-09 interim results, 2025-07 trading update.
• Rapid deleveraging supports valuation re-rating: net debt down from £55.8m (Dec-24) to £50.1m (Jun-25) on first-half free cash flow; targeted ~1x EBITDA by Dec-25. A clean balance sheet plus growing dividend (interim +10%) gives downside protection 2025-09 interim results.

Key risks

• Execution risk on Peters integration: operational synergies skewed to FY27, requiring regulatory approvals for site moves, and supply-chain backlogs at ex-Peters sites have already muted H1 25 ex-Peters suture growth 2025-09 interim results.
• US tariff exposure estimated at £1–2m p.a. (2–4% of EBITDA) plus structural FX risk (~⅓ USD, ⅓ EUR revenue) 2025-09 interim results.
• Royalty cliff/sensitivity precedent: Organogenesis royalty collapse (announced 2023-09) shows AMS's dependence on a few partner relationships and resulted in a profit warning; concentration risk remains in Woundcare OEM partnerships 2023-09 trading statement.

Operating leverage

AMS is a hybrid manufacturer-marketer with a meaningful fixed cost base (R&D £6.9m H1 25, central admin including 1,500+ employees, multiple manufacturing sites in UK/Germany/France/Thailand/India/Czech/Israel), but the COGS line scales with volume — gross margin 53.5% H1 25 means roughly 53p of every incremental £1 of revenue drops toward operating profit before partial cost-base scaling. Surgical adjusted EBITDA margin of 24.9% (H1 25) is below the legacy AMS Surgical run-rate (32.2% H1 24) purely because of Peters mix — pre-acquisition Surgical hit ~30% EBITDA, suggesting a 600bp recovery is achievable if Peters reaches group margin. Were 2026 revenue to come in 10–15% above plan, incremental EBITDA could reasonably add 40–60% to operating profit (given the synergy capture phase). This is moderate operating leverage — meaningful, but nothing like a SaaS platform 2025-09 interim results, 2024-09 interim results.

Value-trap signals

None identified. Disclosure is candid (the 2023 profit warning was transparent), the balance sheet is conservative, dividends have grown (interim +10% three years running), and the business model is structurally growing on demographic tailwinds.

Earnings vs expectations

Pattern across the period: two clear misses, then consistent in-line delivery. The Sept 2023 trading update was a meaningful downgrade (Organogenesis royalty removed + US LiquiBand destocking) — FY23 revenue guidance cut to £124–127m. Since then, FY 2024 results (Jan-25 update: revenues "approximately £177m", EBITDA £40.0–40.5m) and FY 2025 trading update (Jan-26: revenues "approximately £228.5m", EBITDA £49.5–50m) have both come in at the top of guidance ranges. H1 25 was "in line with expectations" with FY reiterated. Net: a stumble two years ago around a royalty stream the company couldn't control, followed by disciplined delivery across the transformative M&A.

Conviction

4 — high.

Anchors: (i) clean and detailed disclosure including segment EBITDA reconciliations and quantified synergy targets; (ii) two converging valuation methods (EV/EBITDA and forward P/E) land in similar range; (iii) recent guidance has been met cleanly.

Limits: (i) the Peters integration is still mid-flight — the 2026 margin and FY26 EPS shape contains genuine uncertainty until commercial synergies prove durable; (ii) the next 12 months include US tariff impact and final completion of integration cost ramp.